Monday, June 15, 2026

POLICY PARALYSIS: Washington Signals Frustration As Seoul’s North Korea Strategy Becomes A Tug-of-War

U.S. envoy urges South Korea to unify its North Korea policy, warning against a conciliatory stance while emphasizing sanctions and dialogue leverage.

Is South Korea the Most Vulnerable Emerging Market to U.S. Rate Hikes? Find Out!

South Korea is most vulnerable to U.S. interest rate shifts, with rising long-term yields impacting its bond market sensitivity.

KOSPI Surges 7% Amid U.S.-Iran Peace Talks: What This Means for Investors

KOSPI surged over 7% amid peace hopes between the U.S. and Iran, driven by semiconductor stocks and a U.S. market rally.

Tag: biopharmaceuticals

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Dongkoo Bio&Pharma Invests 1 Billion KRW in GenomAndCompany: What This Means for ADC Drug Development

Dongkoo Bio&Pharma invests 1 billion KRW in Genome & Company to enhance antibody and ADC drug development strategies.

Celltrion’s Strategic Move: How Local Production in the U.S. Can Mitigate Tariff Risks

Celltrion outlines its Branchburg facility's operations and plans to mitigate tariff risks by establishing local production and a supply system.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

How ABL Bio’s Grabody-B Revolutionizes siRNA Delivery: A Game-Changer for Brain Disease Treatment?

ABL Bio's Grabody-B technology effectively delivers siRNA across the blood-brain barrier, enhancing treatment for brain and systemic diseases.

GC Biopharma Corp Soars After Eight Years on the Back of Immunodeficiency Drug Alyglo, Posting Results in U.S. Market Push

GC Biopharma Corp breaks its fourth-quarter deficit with ALYGLO's success, achieving $106M in annual revenue and plans for future growth.

Unlocking Opportunities: 2025 Bio GMP Training Program Launches at Daejeon University

Daejeon University launched the 2025 Winter BioRG Training Program for biopharmaceuticals, featuring industry experts and hands-on sessions.

Samsung Biologics Unveils Three-Pillar Growth Strategy: How Capacity, Portfolio, and Global Expansion Shape 2026

Samsung Biologics outlines a growth strategy focused on production, portfolio, and global expansion to enhance its CDMO position.

2026: South Korea’s Advanced Regenerative Medicine R&D Investment Expands – What You Need to Know!

The Ministry of Health and Welfare aims to boost investments in advanced regenerative medicine R&D and improve research infrastructure in South Korea.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis partners with Harrow to sell ophthalmic treatments in the U.S., transferring rights from Biogen by 2025.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.